Literature DB >> 8097759

An HIV-1 envelope protein vaccine elicits a functionally complex human CD4+ T cell response that includes cytolytic T lymphocytes.

P E Stanhope1, A Y Liu, W Pavlat, P M Pitha, M L Clements, R F Siliciano.   

Abstract

T cell responses play a critical role in host defense against viral infection. Therefore, the functional properties of HIV-1-specific human T cells induced by an experimental AIDS vaccine were analyzed in detail at the clonal level. Seronegative human volunteers were immunized with a purified recombinant form of the HIV-1 envelope glycoprotein gp160 in a phase I vaccine trial. In a subset of gp160 recipients, this vaccine was shown to elicit a virus-specific CTL response. Antibody blocking and single cell cloning experiments demonstrated that the vaccine-induced cytolytic activity was mediated by CD4+, MHC class II-restricted T cells. Because little is known about the regulation of CD4+ CTL in any system, a detailed analysis of CTL responses in vaccinees was carried out. Longitudinal and cross-sectional studies revealed that the CD4+ CTL response was regulated in a complex manner and was not clearly correlated with MHC class II genotype, Ag dose, or number of immunizations. Cloning studies were carried out to determine what fraction of the vaccine-induced T cells were cytolytic and to examine patterns of cytokine production by vaccine-induced T cells. These experiments demonstrated that, for some vaccinees, CD4+ CTL dominated the in vitro T cell response to gp160 at certain time points. The level of cytolytic activity, which was a stable property of individual clones, varied among clones over a wide and continuous range. Analysis of cytokine secretion by gp160-specific CD4+ T cell clones revealed Th0-, Th1-, and Th2-like patterns, with CD4+ CTL clones showing Th0- or T'1-like patterns. Interestingly, many Th0- and Th1-like CTL clones produced very little IL-2, a finding that may explain the complicated regulation of this response. These results illustrate the complex nature of the human T cell response to subunit vaccines consisting of purified recombinant viral proteins.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8097759

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

1.  Modulation of the immune response to the severe acute respiratory syndrome spike glycoprotein by gene-based and inactivated virus immunization.

Authors:  Wing-pui Kong; Ling Xu; Konrad Stadler; Jeffrey B Ulmer; Sergio Abrignani; Rino Rappuoli; Gary J Nabel
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

Review 2.  Advances in FIV vaccine technology.

Authors:  Elizabeth W Uhl; Marcus Martin; James K Coleman; Janet K Yamamoto
Journal:  Vet Immunol Immunopathol       Date:  2008-01-20       Impact factor: 2.046

Review 3.  Involvement of CD80 in the generation of CD4+ cytotoxic T cells.

Authors:  D Mauri; W J Pichler
Journal:  Immunol Res       Date:  1996       Impact factor: 2.829

4.  Mapping of specific and promiscuous HLA-DR-restricted T-cell epitopes on the Plasmodium falciparum 27-kilodalton sexual stage-specific antigen.

Authors:  C E Contreras; I N Ploton; R F Siliciano; C L Karp; R Viscidi; N Kumar
Journal:  Infect Immun       Date:  1998-08       Impact factor: 3.441

5.  Multiple effector functions mediated by human immunodeficiency virus-specific CD4(+) T-cell clones.

Authors:  P J Norris; M Sumaroka; C Brander; H F Moffett; S L Boswell; T Nguyen; Y Sykulev; B D Walker; E S Rosenberg
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

Review 6.  Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases.

Authors:  D R Lucey; M Clerici; G M Shearer
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

7.  Enhanced activation of human T cell clones specific for virus-like particles expressing the HIV V3 loop in the presence of HIV V3 loop-specific polyclonal antibodies.

Authors:  S Peifang; G L Pira; D Fenoglio; S Harris; M G Costa; V Venturino; V Dessì; G Layton; J Laman; J G Huisman
Journal:  Clin Exp Immunol       Date:  1994-09       Impact factor: 4.330

8.  Differential susceptibility of naive and memory CD4+ T cells to the cytopathic effects of infection with human immunodeficiency virus type 1 strain LAI.

Authors:  T W Chun; K Chadwick; J Margolick; R F Siliciano
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

9.  CD4(+) T cells and gamma interferon in the long-term control of persistent friend retrovirus infection.

Authors:  M Iwashiro; K Peterson; R J Messer; I M Stromnes; K J Hasenkrug
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

10.  Characterization and augmentation of CD4+ cytotoxic T cell lines against melanoma.

Authors:  T Morisaki; D L Morton; A Uchiyama; D Yuzuki; A Barth; D S Hoon
Journal:  Cancer Immunol Immunother       Date:  1994-09       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.